Opinion|Videos|October 25, 2024
CROWN and BRIGHTSTAR Studies: Latest Data Insights
Panelists discuss the key findings from the latest data from the CROWN and BRIGHTSTAR studies, emphasizing efficacy end points and comparing the effectiveness of these regimens with that of others in the treatment landscape for ALK-positive NSCLC.
Advertisement
- Dr Bestvina: Please discuss the key findings from the latest data for the CROWN/BRIGHTSTAR studies.
- CROWN
- Please specifically discuss and emphasize efficacy end points here. How does the efficacy of this regimen compare with that of others in this space?
- BRIGHTSTAR
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5































